Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 30.85%.

  • Phathom Pharmaceuticals' EBITDA Margin rose 4021000.0% to 30.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 145.03%, marking a year-over-year increase of 9509900.0%. This contributed to the annual value of 502.18% for FY2024, which is 240303700.0% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' EBITDA Margin is 30.85%, which was up 4021000.0% from 151.69% recorded in Q2 2025.
  • Phathom Pharmaceuticals' EBITDA Margin's 5-year high stood at 1373.9% during Q1 2022, with a 5-year trough of 10245.6% in Q4 2023.
  • Over the past 4 years, Phathom Pharmaceuticals' median EBITDA Margin value was 176.0% (recorded in 2025), while the average stood at 1077.79%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -107313500bps in 2023, then skyrocketed by 100453000bps in 2024.
  • Phathom Pharmaceuticals' EBITDA Margin (Quarter) stood at 485.75% in 2022, then tumbled by -2209bps to 10245.6% in 2023, then surged by 98bps to 200.3% in 2024, then surged by 85bps to 30.85% in 2025.
  • Its last three reported values are 30.85% in Q3 2025, 151.69% for Q2 2025, and 276.53% during Q1 2025.